QN

9(15):2243-2251 (Oct 10, 1998)

Sheet $\frac{1}{2}$ of $\frac{1}{2}$

FORM PTO-1449

(Use several sheets if necessary)

U.S. Dept. of Commerce Patent and Trademark Office LIST OF DISCLOSURES CITED BY APPLICANT

Atty Docket No. Serial No. P1752R1 09/613,038

Applicant

Grillo-Lopez et al.

Filing Date Group 1636 10 Jul 2000

FOREIGN	PATENT	DOCUMENTS	

Verzeletti et al., "Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host

disease and graft-versus-leukemia: clinical follow-up and improved new vectors" Human Gene Therapy

				TORLIGHTATENT DOCUMEN	13							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Transla Yes	ition No				
QN	92	WO 97/45142	04.12.97	PCT *	•							
an	93	WO 98/42824	01.10.98	PCT •	-							
			OTHER DISCL	OSURES (Including Author, Title, Date	e, Pertinent Pages, etc	e.)	<u> </u>					
an	94	Introna et al., "Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies" <u>Human Gene Therapy</u> 11(4):611-620 (Mar 1, 2000)										
QN	95	McLaughlin et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program" <u>Journal of Clinical Oncology</u> 16(8):2825-2833 (Aug 1998)										

TECH OFNITER 160012900

Examiner

Date Considered 128 lo

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.